Loading clinical trials...

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Onset of Action of Mometasone Furoate (SCH 32088) Nasal Spray 50 mcg/Spray vs Placebo in Seasonal Allergic Rhinitis (Study No. C93-184).

NCT03861559•Organon and Co

View on ClinicalTrials.gov

Summary

This study investigated the onset of symptom relief following initiation of treatment with mometasone furoate (MK-0887/SCH 032088) 200 mcg administered once daily compared with placebo for 14 days.

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has a 2-year history of seasonal allergic rhinitis
•Has a positive skin test response to a local seasonal allergen (current, or performed in investigator's office within the past year)
•Is in good health and free of any unstable, clinically-significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis

Exclusion Criteria

•Women who are pregnant or breastfeeding
•Women of childbearing potential who are not using an acceptable form of birth control
•Has asthma that requires therapy with inhaled or systemic corticosteroids, cromolyn, or nedocromil
•Has significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal, or other significant medical illness or disorder which, in the judgment of the investigator, could interfere with the study, or required treatment which might interfere with the study
•Is on immunotherapy with the exception of maintenance therapy
•Has a clinically significant upper respiratory or sinus infection
•Has used an investigational drug within the previous 30 days
•Has nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow
•Has a history of multiple drug allergies or an allergy to antihistamines or corticoids
•Has dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines, in the opinion of the investigator
+2 more criteria

Key Dates

Start Date

March 30, 1994

Primary Completion Date

June 27, 1994

Completion Date

July 7, 1994

Last Updated

February 9, 2022

Enrollment

201

ACTUAL participants

Conditions

Rhinitis, Allergic, Seasonal

Interventions

mometasone furoate nasal spray

DRUG

placebo nasal spray

DRUG

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

NCT00127647

Rhinitis, Allergic, Seasonal

View study

COMPLETEDPHASE3

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

NCT00406783

Rhinitis, Allergic, SeasonalRhinitis, Allergic, Perennial

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

Inclusion Criteria

Exclusion Criteria

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)